PTO/AIA/15 (03-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paoerwork Reduction Act of 1995 no oersons are reauired to resoond to a collection of information unless it disola sa valid OMB control number
`15660-189 (BLS 102USD1f
`UTILITY
`First Named Inventor N. CHIDAMBARAM
`PATENT APPLICATION
`TRANSMITTAL
`
`Title
`
`LIQUID DOSAGE FORMS OF SODIUM NAPROXEN
`
`Attorney Docket No.
`
`(Only for new nonprovisional applications under 37 CFR 1.53(b))
`
`Express Mail Label No.
`
`./
`
`APPLICATION ELEMENTS
`See MPEP chapter 600 concerning utility patent application contents.
`
`/"
`
`'
`
`1.0 Fee Transmittal Form
`(PTO/SB/17 or equivalent)
`
`2.o Applicant asserts small entity status.
`See 37 CFR 1.27
`
`3.o
`
`Applicant certifies micro entity status. See 37 CFR 1.29.
`Applicant must attach form PTO/SB/15A orB or equivalent.
`[Total Pages 18
`4.0 Specification
`Both the claims and abstract must start on a new page.
`(See MPEP § 608.01(a)for information on the preferred arrangement)
`12.0 English Translation Document
`l
`(if applicable)
`l 13.0 Information Disclosure Statement
`(PTO/SB/08 or PT0-1449)
`
`ADDRESS TO:
`
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`ACCOMPANYING APPLICATION PAPERS
`
`10. 0
`
`Assignment Papers
`(cover sheet & document(s))
`Name of Assignee BANNER LIFE SCIENCES
`
`l
`
`11. 0
`
`37 CFR 3.73(c) Statement
`(when there is an assignee)
`
`0
`
`Power of Attorney
`
`0
`
`Copies of citations attached
`
`14.0 Preliminary Amendment
`
`15.0 Return Receipt Postcard
`(MPEP § 503) (Should be specifically itemized)
`
`16.0 Certified Copy of Priority Document(s)
`(if foreign priority is claimed)
`
`17.0 Nonpublication Request
`Under 35 U.S. C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35
`or equivalent.
`Other: REQUEST FOR PARTICIPATION IN THE PATENT PROSECUTION HIGHWAY
`
`18.0
`
`5. 0
`
`Drawing(s) (35 U.S.C. 113)
`
`[Total Sheets 0
`[Total Pages 2
`6. Inventor's Oath or Declaration
`(including substitute statements under 37 CFR 1. 64 and assignments
`serving as an oath or declaration under 37 CFR 1. 63(e))
`
`a. 0
`
`b. 0
`
`Newly executed (original or copy)
`
`A copy from a prior application (37 CFR 1.63(d))
`
`7.0 Application Data Sheet
`*See note below.
`See 37 CFR 1.76 (PTO/AIA/14 or equivalent)
`
`8.
`
`CD-ROM or CD-R
`in duplicate, large table, or Computer Program (Appendix)
`
`Landscape Table on CD
`
`0
`9. Nucleotide and/or Amino Acid Sequence Submission
`(if applicable, items a.- c. are required)
`
`a. 0
`
`b. 0
`
`Computer Readable Form (CRF)
`
`Specification Sequence Listing on:
`
`i. 0 CD-ROM or CD-R (2 copies); or
`
`ii.O Paper
`
`c. 0
`
`Statements verifying identity of above copies
`
`*Note: (1) Benefit claims under 37 CFR 1.78 and foreign priority claims under 1.55 must be included in an Application Data Sheet (ADS).
`(2) For applications filed under 35 U.S.C. 111, the application must contain an ADS specifying the applicant if the applicant is an
`assignee, person to whom the inventor is under an obligation to assign, or person who otherwise shows sufficient proprietary
`interest in the matter. See 37 CFR 1.46(b).
`19. CORRESPONDENCE ADDRESS
`
`The address associated with Customer Number: 129259
`
`0
`
`OR 0
`
`Correspondence address below
`
`Name
`
`Address
`
`City
`
`Country
`
`Signature
`
`Name
`(Print/Type)
`
`State I
`I
`I Telephone I
`May 20, 2016
`/Bernard A. Brown II/
`Registration No. 60543
`Bernard A. Brown II
`(Attorney I Agent)
`This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO
`to process) an application. Confidentiality is governed by 35 U.S. C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete,
`including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on
`the amount oftime you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND
`TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`If you need assistance in completing the form, ca/11-800-PT0-9199 and select option 2.
`
`I Zip Code
`I
`
`Email
`
`Date
`
`Petitioner - Catalent Pharma Solutions
`Ex. 1008, Pg. 1 of 236
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your
`submission of the attached form related to a patent application or patent. Accordingly, pursuant to the
`requirements of the Act, please be advised that: (1) the general authority for the collection of this information is
`35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which
`the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission
`If you do not furnish the requested information, the U.S. Patent and
`related to a patent application or patent.
`Trademark Office may not be able to process and/or examine your submission, which may result in termination
`of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1. The information on this form will be treated confidentially to the extent allowed under the Freedom of
`Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of
`records may be disclosed to the Department of Justice to determine whether disclosure of these
`records is required by the Freedom of Information Act.
`2. A record from this system of records may be disclosed, as a routine use, in the course of presenting
`evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in
`the course of settlement negotiations.
`3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress
`submitting a request involving an individual, to whom the record pertains, when the individual has
`requested assistance from the Member with respect to the subject matter of the record.
`4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency
`having need for the information in order to perform a contract. Recipients of information shall be
`required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C.
`552a(m).
`5. A record related to an International Application filed under the Patent Cooperation Treaty in this
`system of records may be disclosed, as a routine use, to the International Bureau of the World
`Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`6. A record in this system of records may be disclosed, as a routine use, to another federal agency for
`purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act
`(42 U.S.C. 218(c)).
`7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General
`Services, or his/her designee, during an inspection of records conducted by GSA as part of that
`agency's responsibility to recommend improvements in records management practices and programs,
`under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the
`GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or
`Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
`8. A record from this system of records may be disclosed, as a routine use, to the public after either
`publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35
`U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine
`use, to the public if the record was filed in an application which became abandoned or in which the
`proceedings were terminated and which application is referenced by either a published application, an
`application open to public inspection or an issued patent.
`9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local
`law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or
`regulation.
`
`Petitioner - Catalent Pharma Solutions
`Ex. 1008, Pg. 2 of 236
`
`

`

`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`PTO/AIA/14
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`15660-1 89 (BLS 1 02USD1)
`
`Application Number
`
`Title of Invention
`
`LIQUID DOSAGE FORMS OF SODIUM NAPROXEN
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document
`may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2:
`D Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37
`
`CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`Inventor
`Legal Name
`
`1
`
`Prefix Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`Nachiappan
`Residence Information (Select One) @ US Residency
`I State/Province
`Sandy
`City
`
`Chidambaram
`0 Active US Military Service
`0 Non US Residency
`I Country of Residence i
`I US
`I UT
`
`Mailing Address of Inventor:
`
`Address 1
`
`Address2
`
`8410 S Handcart Circle
`
`City
`
`I Sandy
`Postal Code
`
`1 84070
`
`Inventor
`Legal Name
`
`2
`
`I State/Province
`I Country i
`1 us
`
`I UT
`
`Prefix Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`A
`Aqeel
`Residence Information (Select One) @ US Residency
`I State/Province
`High Point
`City
`
`Fatmi
`0 Active US Military Service
`0 Non US Residency
`I Country of Residence i
`I US
`I NC
`
`Mailing Address of Inventor:
`
`Address 1
`
`Address2
`
`41 25 Premier Drive
`
`City
`
`I High Point
`Postal Code
`
`I State/Province
`I Country i
`1 us
`All Inventors Must Be Listed -Additional Inventor Information blocks may be generated
`within this form by selecting the Add button.
`
`1 27265
`
`I NC
`
`I Add
`
`I
`
`Correspondence Information:
`
`WEB ADS 1.0
`
`Petitioner - Catalent Pharma Solutions
`Ex. 1008, Pg. 3 of 236
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. OMB 0651-D032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`15660-1 89 (BLS 1 02USD1)
`
`Application Number
`
`Title of Invention
`
`LIQUID DOSAGE FORMS OF SODIUM NAPROXEN
`
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`D An Address is being provided for the correspondence Information of this application.
`129259
`Customer Number
`
`Email Address
`
`Email Address
`
`Email Address
`
`bbrown@brinksgilson.com
`
`usebrinks-nc@brinksgilson.com
`
`Patheon-docketing@cpaglobal.com
`
`Application Information:
`
`I Add Email
`I Add Email
`
`I
`I
`
`I Remove Email I
`I Remove Email I
`I Remove Email I
`
`Title of the Invention
`
`Attorney Docket Number
`
`LIQUID DOSAGE FORMS OF SODIUM NAPROXEN
`I Small Entity Status Claimed D
`
`15660-189 (BLS 102USD1)
`
`Application Type
`
`Subject Matter
`
`Total Number of Drawing Sheets (if any)
`
`I
`
`I Suggested Figure for Publication (if any)
`
`I
`
`Filing By Reference:
`Only complete this section when filing an application by reference under 35 U.S.C. 111 (c) and 37 CFR 1 .57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").
`
`For the purposes of a filing date under 37 CFR 1 .53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 1 .57(a).
`
`Application number of the previously
`filed application
`
`Filing date {YYYY-MM-DD)
`
`i-
`Intellectual Property Authority or Country
`
`Publication Information:
`D Request Early Publication (Fee required at time of Request 37 CFR 1.21 9)
`35 u.s.c.
`Request Not to Publish. I hereby request that the attached application not be published under
`D 1 22(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an
`application filed in another country, or under a multilateral international agreement, that requires publication at eighteen
`months after filing.
`
`Representative Information:
`
`Representative information should be provided for all pract1t1oners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1 .32).
`Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number
`will be used for the Representative Information during processing.
`
`WEBADSl.O
`
`Petitioner - Catalent Pharma Solutions
`Ex. 1008, Pg. 4 of 236
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. OMB 0651-D032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`15660-1 89 (BLS 1 02USD1)
`
`Application Number
`
`Title of Invention
`
`LIQUID DOSAGE FORMS OF SODIUM NAPROXEN
`
`Please Select One:
`
`@ Customer Number
`
`Customer Number
`
`129259
`
`I 0 US Patent Practitioner
`
`IO Limited Recognition (37 CFR 11 .9)
`
`Prefix
`
`Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`Registration Number
`
`Prefix
`
`Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`I Remove
`
`I
`
`I Remove
`
`I
`
`Registration Number
`
`Additional Representative Information blocks may be generated within this form by
`selecting the Add button.
`
`Domestic Benefit/National Stage Information:
`35 U.S.C. 1 1 9(e}, 120, 121, 36S(c}, or 386(c) or
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`(YYYY-MM-DD)
`
`Division of
`
`14977808
`
`2015-12-22
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`(YYYY-MM-DD)
`
`14977808
`
`Continuation of
`
`11367238
`
`2006-03-03
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`(YYYY-MM-DD)
`
`11367238
`
`Claims benefit of provisional
`
`60659679
`
`2005-03-08
`
`Additional Domestic Benefit/National Stage Data may be generated within this form by
`selecting the Add button.
`
`Foreign Priority Information:
`
`WEB ADS 1.0
`
`Petitioner - Catalent Pharma Solutions
`Ex. 1008, Pg. 5 of 236
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. OMB 0651-D032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`15660-1 89 (BLS 1 02USD1)
`
`Application Number
`
`Title of Invention
`
`LIQUID DOSAGE FORMS OF SODIUM NAPROXEN
`
`section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`lca,nsltitultes the claim for priority as required by 35 U.S.C. 1 19(b) and 37 CFR 1 .55. When priority is claimed to a foreign application
`is eligible for retrieval under the priority document exchange program (PDX) thj information will be used by the Office to
`1au1tornat:ically attempt retrieval pursuant to 37 CFR 1 .55(i)(1) and (2). Under the PDX program, applicant bears the ultimate
`I resmmsibillitv for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`lonope,rtvoffice, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1 .55(g)(1 ).
`
`Additional Foreign Priority Data may be generated within this form by selecting the Add
`button.
`
`Statement under 37 CFR 1.55 or 1.78 for AlA (First Inventor to File) Transition
`Applications
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`D 16,2on.
`NOTE: By providing this statement under 37 CFR 1.55 or 1 .78, this application, with a filing date on or after March
`16, 2013, will be examined under the first inventor to file provisions of the AlA.
`
`WEBADSl.O
`
`Petitioner - Catalent Pharma Solutions
`Ex. 1008, Pg. 6 of 236
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. OMB 0651-D032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`15660-1 89 (BLS 1 02USD1)
`
`Application Number
`
`Title of Invention
`
`LIQUID DOSAGE FORMS OF SODIUM NAPROXEN
`
`Authorization or Opt-Out of Authorization to Permit Access:
`
`When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to
`permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in
`subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see
`paragraph Bin subsection 1 below).
`
`Should applicant choose not to provide an authorization identified in subsection 1 below, applicant must opt-out of the
`authorization by checking the corresponding box A orB or both in subsection 2 below.
`
`NOTE: This section of the Application Data Sheet is ONLY reviewed and processed with the INITIAL filing of an application.
`After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access
`by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.
`
`1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Priority Document Exchange (POX)- Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned
`hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean
`Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World
`Intellectual Property Organization (WI PO), and any other foreign intellectual property office participating with the USPTO in a
`bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant
`patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign
`or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and
`(3) the date of filing of this Authorization. See 37 CFR 1. 14(h)(1 ).
`
`B. Search Results from U.S. Application to EPO- Unless box Bin subsection 2 (opt-out of authorization) is checked, the
`undersigned hereby grants the USPTO authority to provide the EPO access to the bibliographic data and search results from
`the instant patent application when a European patent application claiming priority to the instant patent application is filed. See
`37 CFR 1.14(h)(2).
`
`The applicant is reminded that the EPO's Rule 141 (1) EPC (European Patent Convention) requires applicants to submit a copy of
`search results from the instant application without delay in a European patent application that claims priority to the instant
`application.
`
`2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Applicant DOES NOT authorize the USPTO to permit a participating foreign IP office access to the instant
`D application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any
`documents and information identified in subsection 1 A above.
`
`B. Applicant DOES NOT authorize the USPTO to transmit to the EPO any search results from the instant patent
`D application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.
`
`NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in
`accordance with 37 CFR 1.1 4.
`
`WEB ADS 1.0
`
`Petitioner - Catalent Pharma Solutions
`Ex. 1008, Pg. 7 of 236
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. OMB 0651-D032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`15660-1 89 (BLS 1 02USD1)
`
`Application Number
`
`Title of Invention
`
`LIQUID DOSAGE FORMS OF SODIUM NAPROXEN
`
`Applicant Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`1
`Applicant
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`I
`
`lo Legal Representative under 35 U.S.C. 1 1 7
`® Assignee
`lo
`0 Person to whom the inventor is obligated to assign.
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`lo Joint Inventor
`
`I Clear
`
`Person who shows sufficient proprietary interest
`
`Name of the Deceased or Legally Incapacitated Inventor:
`
`I
`
`If the Applicant is an Organization check here.
`
`~
`
`Organization Name
`
`I BANNER LIFE SCIENCES LLC
`
`Mailing Address Information For Applicant:
`
`Address 1
`
`Address 2
`
`City
`Country 1 I US
`
`Phone Number
`
`Email Address
`
`41 25 Premier Drive
`
`High Point
`
`336.812.0000
`
`I
`
`State/Province
`
`Postal Code
`
`Fax Number
`
`NC
`
`27265
`
`336.812.0000
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`WEBADSl.O
`
`Petitioner - Catalent Pharma Solutions
`Ex. 1008, Pg. 8 of 236
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. OMB 0651-D032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`15660-1 89 (BLS 1 02USD1)
`
`Application Number
`
`Title of Invention
`
`LIQUID DOSAGE FORMS OF SODIUM NAPROXEN
`
`Assignee Information including Non-Applicant Assignee Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 ofTitle 37 of
`CFR to have an assignment recorded by the Office.
`
`1
`Assignee
`Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application
`publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an
`applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application
`publication.
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`Prefix
`
`Given Name
`
`Middle Name
`
`Family Name
`
`D
`
`Suffix
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`Address 1
`
`Address 2
`
`City
`
`Country i
`
`I
`Phone Number
`
`Email Address
`
`I
`
`State/Province
`
`Postal Code
`
`Fax Number
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`WEB ADS 1.0
`
`Petitioner - Catalent Pharma Solutions
`Ex. 1008, Pg. 9 of 236
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. OMB 0651-D032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`15660-1 89 (BLS 1 02USD1)
`
`Application Number
`
`Title of Invention
`
`LIQUID DOSAGE FORMS OF SODIUM NAPROXEN
`
`Signature:
`NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1 .33(b). However, if this Application Data Sheet
`is submitted with the INITIAL filing of the application and either box A or B is not checked in subsection 2 of the
`"Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance
`with 37 CFR 1.14(c).
`This Application Data Sheet must be signed by a patent practitioner if one or more of the applicants is a juristic entity (e.
`g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner,
`all joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g.,
`see USPTO Form PTO/AIA/81) on behalf ofall joint inventor-applicants.
`See 37 CFR 1 .4(d) for the manner of making signatures and certifications.
`
`Signature
`
`/Bernard A. Brown II/
`
`Date (YYYY -MM-DD)
`
`First Name
`
`Bernard
`
`I Last Name
`
`I Brown
`
`I Registration Number
`
`60543
`
`Additional Signature may be generated within this form by selecting the Add button.
`
`WEB ADS 1.0
`
`Petitioner - Catalent Pharma Solutions
`Ex. 1008, Pg. 10 of 236
`
`

`

`PT0/~6/0·tA (139-0··~)
`fl..pprr..·:n,;~}~ tOt ~:se thrO·L.:·gh 0?13.1/20·06. 0~·~8 C5S1-0iJ32
`U.S P<!\~11! ;:;r;i:i Traden<ar~; Office: U.S. DEPARTMENT OF COMMERCE
`....... J~f~:der ~he P~~o~rwofk Rt-~d;:.Jc•i·or· Acto"! i~3g5 ~o p~r5c~~~·(lt~ reaL·ir-ed to .. 't1~oond ro a m\le:ction of mk~rn-.,,ation tm.!~:i;>~? if displavs a va}ld OMB -co.rit~t1i m . .m .. ber
`
`DECLARATION (37 CFR 1.63) FOR UTILITY OR DESiGN APPLICATION USING AN
`APPLICATfON DATA SHEET (37 CFR 1.76)
`
`Title of
`Invention
`
`SOLVENT SYSTEM FOR ENHANCING THE SOLUBILITY OF PHARMACEUTICAL
`AGENTS
`
`f\s the befow named inventor(s). !/we declare that:
`
`Thls declaration is directed to
`
`n The attached application, or
`
`Application No< __ 11_1_3_6_7_,2_3_8 ____ . filed on _M_a_r_c_h_3_, _2_0_0_6 ______ _
`D as amended on ______________________ {if applicable);
`lfwe believe that Uwe am/are the original and first inventor(s) of the subject matter which is dairned and for \Nhich a patent is
`SC!HfJht
`
`i!we have reviewed and understand tile conb:mts of tr1e above-identffled application. including the claims. as amended by any
`amendment speciflcaHy referred to above:
`
`1/we acknowledge the duty to disciose to the United States Patent and lrademark Office a!l Information known to me/us to be
`materiai to patentability as def1ned in 37 CFR 1.56; including for continuation-in-part appJications. material informatior1 which
`became available between the filing date of the prior application and the national or PCT International filing date of the
`conttnuation-·irY-part applicat;on.
`
`Air statements made hereifl of my/ovvn knowledge are true, all statements made herem on Information and belief are believed
`to be t!we, and f<Hther that these statements vvere made 'INith the knowledge tllat wi.l!ful false statements and the like are
`punishable by fine or imp1·isonment, or botr1, under 18 U.S.C. 1001. and may jeopardize the validity of th.e application or any
`patent issuing ihereon.
`
`FULL NAME OF !NVENTOR(S)
`
`Signature: __________________________ Citizen ot -'l..,_n,.d"'la"'". - - - - - - - - - - -
`
`Inventor tvvo: &J~el Fatrni ·o---------------------------~----
`
`t-S_i£_1!'_,a_tu_· r_e_: :::=-·:':.1\±---'~-_-..... _+-.-~....,-~~):..._Ji_·_.· _ .... ___ ~-_l) ___________ __ __ _ _ Ci.tizen of: United States
`
`Signature: ____________________________ Citizen of:
`
`lrwentor fou r : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - · - - - - -
`
`Signature: ___________________________ CW.wn of:-----~--~~~---
`
`0
`. ................ addlUonal fot·m(s) .:;tiached J1ereto.
`Additionai inventor:; or aiE:ga.l representative are bemg rlllmed on"....................... .
`Thio coi,et:t:on oi in!ormal:or; >s requ1re~ l:ly 35 I.J.S.C. ii5 i.llt<i 37 CFR ·1 e:J. Trw mlom1al!OillS required t:w obtam orret~>>n a l:lefleht by- tne pubi>C wh:cn :s U1 f:!to
`{and 0-y ·tbtj USPTO ~o prcc~&s} ·.a~l- :app!icat.l:en. Ccnfr~ef1tjality :s goverf1~d by 35 u .. s..c._ ·~22 and 37 CFR ·1·.1 ~ and ~~-14. This· c.ol~ect~or~ ;s es:.Jm:.ated tt.) wt:e ·~
`mt:1ute ~c ·ccmpfet~. i~C.!L;C~ng g~thefing, prepati:~1g, and subr;1jtrjng the cgmptete.d a.pp!}eation t"ortn ~o me L,JSPTO .. T~rn.~ ~·Vt!: VW)'' dependirrg upoG the .int1ividuBJ
`r;.&s-e. Any c.cmm-*-nu~ on ~rn·~ amourn o~ ttme you rcquim to .r;omplcte th4~ tbrrn·amficr :;;ugge:Slkms fer r~dLl'Wing tfJi$ hwtJen. s~lO.u~d be Sen:t to the Gh~e1 ~nfn:mBt~on
`Offlt.~r. U.S PW(;n\ •md frilct>:mark Cfffce, lJ S. Dl'lpartn;~r,tcf Commcn::e, P.O. Sex 14:.:0, fl!e;<«Mrla. VA. 22313·145(i. DO NOT SEND FEES OR COMPLETED
`~(JR;,.;s TD TM:S ADDRESS .. SEND TO: Commlsstoner tor Patilrlts, P.O, Box 1450. Alexandria, VA 22313-·t<ISQ,
`
`Petitioner - Catalent Pharma Solutions
`Ex. 1008, Pg. 11 of 236
`
`

`

`PTO/SBID1A (09-04)
`Approved for use through 07/31/2006. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Pacerworil Reduction Act of 1995 no _persons are reaulred to resoond to a collection of Jnronnallon unless If dlsclavs a valid OMB control number.
`
`DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
`APPLICATION DATA SHEET (37 CFR 1.76)
`
`ntle of
`Invention
`
`SOLVENT SYSTEM FOR ENHANCING THE SOLUBILITY OF PHARMACEUTICAL
`AGENTS
`
`As the below named inventor(s), 1/we declare that
`
`This declaration is directed to:
`
`[{] The attached application, or
`
`D Application No . - - - - - - - - - · filed on - - - - - - - - - - - - - '
`D as amended on __________________ (if applicable);
`
`1/we believe that 1/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is
`sought;
`
`1/we have reviewed and understand the contents of the above-Identified application, including the claims, as amended by any
`amendment specifically referred to above;
`
`J/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be
`material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which
`became available between the filing date of the prior appllcatlon and the national or PC